Abstract
Sickle cell disease (SCD) and beta-thalassemia (also referred to as β-thalassemia) are common hereditary hemoglobinopathies with differing pathophysiologies and clinical courses. However, patients with both diseases exhibit increased platelet and coagulation activation, as well as decreased levels of natural anticoagulant proteins. In addition, they are characterized by thrombotic complications that may share a similar pathogenesis. The pathogenesis of hypercoagulability is likely multifactorial, with contributions from the abnormal red blood cell (RBC) phospholipid membrane asymmetry, ischemia-reperfusion injury, and chronic hemolysis with resultant nitric oxide depletion. More studies are needed to better define the contribution of hemostatic activation to the pathophysiology of SCD and beta-thalassemia. Furthermore, adequately controlled studies using anticoagulants and antiplatelet agents are warranted to define the role of hypercoagulability in specific complications of these diseases.
Keywords: Sickle cell disease, beta-thalassemia, thrombosis, hypercoagulable state, platelet activation
Current Molecular Medicine
Title: Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Volume: 8 Issue: 7
Author(s): Sylvia T. Singer and Kenneth I. Ataga
Affiliation:
Keywords: Sickle cell disease, beta-thalassemia, thrombosis, hypercoagulable state, platelet activation
Abstract: Sickle cell disease (SCD) and beta-thalassemia (also referred to as β-thalassemia) are common hereditary hemoglobinopathies with differing pathophysiologies and clinical courses. However, patients with both diseases exhibit increased platelet and coagulation activation, as well as decreased levels of natural anticoagulant proteins. In addition, they are characterized by thrombotic complications that may share a similar pathogenesis. The pathogenesis of hypercoagulability is likely multifactorial, with contributions from the abnormal red blood cell (RBC) phospholipid membrane asymmetry, ischemia-reperfusion injury, and chronic hemolysis with resultant nitric oxide depletion. More studies are needed to better define the contribution of hemostatic activation to the pathophysiology of SCD and beta-thalassemia. Furthermore, adequately controlled studies using anticoagulants and antiplatelet agents are warranted to define the role of hypercoagulability in specific complications of these diseases.
Export Options
About this article
Cite this article as:
Singer T. Sylvia and Ataga I. Kenneth, Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia, Current Molecular Medicine 2008; 8 (7) . https://dx.doi.org/10.2174/156652408786241366
DOI https://dx.doi.org/10.2174/156652408786241366 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews The Protein Therapy of Kallikrein in Cerebral Ischemic Reperfusion Injury
Current Medicinal Chemistry Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy A Novel Multi-Target Drug Screening Strategy Directed Against Key Proteins of DAPk Family
Combinatorial Chemistry & High Throughput Screening Biological Importance, Therapeutic Benefit and Analytical Aspects of Bioactive Flavonoid Pectolinarin in the Nature
Drug Metabolism Letters From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Biosynthetic Pathways of Bioactive N-Acylethanolamines in Brain
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Biomarkers Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology